Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in LMIC
NCT07265232Phase 3Withdrawn
- Sponsor
- Lantu Biopharma
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 3 trial of vesemnogene lantuparvovec in spinal muscular atrophy (SMA), sponsored by Lantu Biopharma. Planned start Oct 2025; status: withdrawn.
02
Drugs
vesemnogene lantuparvovec
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT07265232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07265232.